Several companies will head to the FDA seeking approval of new Duchenne muscular dystrophy treatments next year but the death of a patient taking Sarepta’s Elevidys raises important safety questions.

For decades microtubule-targeting agents (MTAs) have been a cornerstone of cancer treatment regimens and continue to be heavily employed as backbone chemotherapy in combination with new targeted ...

Transcript of Signal Chat Is Published as Criticism Mounts Over Leak The full exchange of messages about U.S. strikes in Yemen among top Trump administration officials on Signal was published by ...

Scientists have developed a new method that can grow motor neurons from skin cells, which may serve as a platform for ALS ...